{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:30:53Z","timestamp":1794349853805,"version":"4.9.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.neurot.2025.e00537","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T21:17:08Z","timestamp":1738099028000},"page":"e00537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study"],"prefix":"10.1016","volume":"22","author":[{"given":"Elena","family":"Barbuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Castiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Tomasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Borriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Brescia","family":"Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00537_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00537_bib2","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology [Internet]"},{"key":"10.1016\/j.neurot.2025.e00537_bib3","unstructured":"ClinicalTrials.gov Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS) [NCT03535298]. U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03535298. Accessed 18 January, 2024."},{"key":"10.1016\/j.neurot.2025.e00537_bib4","unstructured":"ClinicalTrials.gov Traditional Versus Early Aggressive Ther- apy for Multiple Sclerosis Trial (TREAT-MS) [NCT03500328]. U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03500328. Accessed 18 January, 2024."},{"issue":"4","key":"10.1016\/j.neurot.2025.e00537_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00537_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00537_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","article-title":"A\u00a0systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis","volume":"9","author":"Giovannoni","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2025.e00537_bib8","article-title":"Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials","volume":"15","author":"Wu","year":"2024","journal-title":"Front Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00537_bib9","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.neurot.2025.e00537_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00537_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00537_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00537_bib13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00537_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00537_bib15","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00537_bib16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00537_bib17","unstructured":"Common Terminology criteria for adverse events (CTCAE) version 5. Published: november 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"issue":"5","key":"10.1016\/j.neurot.2025.e00537_bib19","first-page":"1388","article-title":"Clinical effects of natalizumab on multiple sclerosis appear early in treatment course","volume":"260","author":"Kappos","year":"2013","journal-title":"J\u00a0Neurol"},{"issue":"19","key":"10.1016\/j.neurot.2025.e00537_bib20","article-title":"Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis","volume":"93","author":"Barkhof","year":"2019","journal-title":"Neurology [Internet]"},{"key":"10.1016\/j.neurot.2025.e00537_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221142924","article-title":"Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score\u2013matched study","volume":"15","author":"Pape","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00537_bib22","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s10072-023-06608-z","article-title":"The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis","volume":"44","author":"Boz","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00537_bib23","article-title":"Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis","volume":"19","author":"Zhu","year":"2022","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00537_bib24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s13311-022-01202-1","article-title":"Comparative effectiveness of natalizumab versus anti-CD20 in highly active relapsing\u2013remitting multiple sclerosis after fingolimod withdrawal","volume":"19","author":"Rollot","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00537_bib25","article-title":"Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: a propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments","volume":"16","author":"Muros-Le Rouzic","year":"2024","journal-title":"J\u00a0Cent Nerv Syst Dis"},{"key":"10.1016\/j.neurot.2025.e00537_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105594","article-title":"NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab","volume":"87","author":"Signoriello","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00537_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.52118","article-title":"A\u00a0comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis","author":"Iaffaldano","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2025.e00537_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.863105","article-title":"Safety, adherence and persistence in a real-world cohort of German MS patients newly treated with ocrelizumab: first insights from the CONFIDENCE study","volume":"13","author":"Weber","year":"2022","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00537_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/ene.15142","article-title":"Ocrelizumab treatment in multiple sclerosis: a Danish population-based cohort study","volume":"29","author":"Pontieri","year":"2022","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00537_bib30","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/neurolint16020029","article-title":"Utilization of ocrelizumab within different treatment strategies for multiple sclerosis: a 5-year population-based study","volume":"16","author":"Moccia","year":"2024","journal-title":"Neurol Int"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T12:58:50Z","timestamp":1751029130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1878747925000157"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00537","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00537"}}